IP Verse

A Method Of Increasing The Productivity Of Eucaryotic Cells In The Production Of Recombinant Fviii - EP2707387

The patent EP2707387 was granted to Octapharma on Dec 25, 2019. The application was originally filed on May 14, 2012 under application number EP12721821A. The patent is currently recorded with a legal status of "Revoked".

EP2707387

OCTAPHARMA
Application Number
EP12721821A
Filing Date
May 14, 2012
Status
Revoked
Sep 30, 2024
Grant Date
Dec 25, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

WALLINGER RICKER SCHLOTTER TOSTMANNSep 25, 2020ZWICKERADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO0170968
DESCRIPTIONWO2006103258
DESCRIPTIONWO2007003582
DESCRIPTIONWO2008006494
INTERNATIONAL-SEARCH-REPORTUS2008131934
INTERNATIONAL-SEARCH-REPORTWO2006103258
INTERNATIONAL-SEARCH-REPORTWO2008006494
OPPOSITIONUS5804420
OPPOSITIONUS9120873
OPPOSITIONWO2006103258
OPPOSITIONWO2010034428
OPPOSITIONWO2010089151
OPPOSITIONWO2011012725

Non-Patent Literature (NPL) Citations (10) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ANONYMOUS, "Optimum growth flasks", Thomson Instrument Company, pages 1 - 10-
OPPOSITION- P. CZERMAK, R. Portner, and A. Brix, "Chapter 4 / Special Engineering Aspects", P. CZERMAK, R. Portner, and A. Brix, R. Eibl et al.,, CELL AND TISSUE REACTION ENGINEERING : Principles and Praxtice, Springer-Verlag Berlin Heidelberg, (2009), pages 83 - 172, XP055739471-
OPPOSITION- ZHOU et al., "Mammalian Cell Bioreactors", Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology, (20100000), pages 1 - 10, XP055650285
OPPOSITION- PESHWA et al., "Cultivation of mammalian cells as aggregates in bioreactors: Effect of calcium concentration of spatial distribution of viability", Biotechnology and Bioengineering, (19930000), vol. 41, pages 179 - 187, XP002927250
OPPOSITION- Alvin W Nienow, "Reactor engineering in large scale animal", cell, (20060000), vol. 50, doi:10.1007/s10616-006-9005-8, pages 9 - 33, XP019393910
OPPOSITION- Sanchez Perez J A; Rodriguez Porcel E M; Casas Lopez J L; Fernandez Sevilla J M; Chisti Y, "Shear rate in stirred tank and bubble column bioreactors", Chemical Engineering, (20060000), vol. 124, doi:10.1016/j.cej.2006.07.002, pages 1 - 5, XP028035897
OPPOSITION- Mille Petersen Kolind; Peder Lisby Nørby; Martin Werner Berchtold; Laust Bruun Johnsen, "Optimisation of the Factor VIII yield in mammalian cell cultures by reducing the membrane bound fraction", JOURNAL OF BIOTECHNOLOGY, (20110000), vol. 151, no. 4, pages 357 - 362, XP002668206
OPPOSITION- SENGER RYAN S; KARIM M NAZMUL, "Effect of shear stress on intrinsic CHO culture state and glycosylation of recombinant tissue-type plasminogen activator protein", Biotechnol Prog., (20030000), vol. 19, no. 4, doi:10.1021/BP025715F, pages 1199 - 1209, XP002600489
OPPOSITION- TSAO Y-S; ET AL, "Development and improvement of a serum-free suspension process for the production of recombinant adenoviral vectors using HEK293 cells.", Cytotechnology, (20010000), vol. 37, doi:10.1023/A:1020555310558, pages 189 - 198, XP009036376
OPPOSITION- Schwartz Bruce A; Sandberg Helena; Agerkvist Irene; Kannicht Christoph; Ramström Margareta; Stenlund Peter; Oswaldsson Ulla; Brunberg Tobias, "The First Human Cell Line Recombinant Factor VIII (Human-cl rhFVIII) - Functional Properties and Differences From Currently Available Recombinant Factor VIII Products", Blood, (20090000), vol. 114, no. 22, page 1298, XP086687018

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents